Below is a statement from Global HIV Vaccine Enterprise executive director, Dr. Alan Bernstein.  The Enterprise (http://www.hivvaccineenterprise.org) is a global alliance of researchers, funders, policy makers and advocates that includes the African AIDS Vaccine Program, the AIDS Vaccine Advocacy Coalition (AVAC), the AIDS Vaccine Asian Network, the Bill & Melinda Gates Foundation, the Canadian HIV Vaccine Initiative, the Center for HIV/AIDS Vaccine Immunology, the Chinese AIDS Vaccine Initiative, the Collaboration for AIDS Vaccine Discovery (CAVD), the Department for International Development, the European Commission, Europrise, Eurovacc, GlaxoSmithKline, the HIV Vaccine Trials Network (HVTN), the International AIDS Vaccine Initiative (IAVI), Merck & Co. Inc., the National Agency for AIDS Research (ANRS), the National Institute of Allergy and Infectious Diseases (NIAID), Novartis Vaccines, sanofi pasteur, the South African AIDS Vaccine Initiative (SAAVI), the U.S. Military HIV Research Program (MHRP), UNAIDS, USAID, Vaccine Research Center (VRC), Wellcome Trust and the World Health Organization (WHO).

Dr. Bernstein is available to speak with journalists to help put the Thai trial results into perspective and to comment on their significance for the future of HIV vaccine research.  To interview Dr. Bernstein, please contact Mark Aurigemma at (212) 600-1960, (646) 270-9451 or mark@aucomm.net; or Jennifer Brunet at (212) 46i-3693 or jbrunet@vaccineenterprise.org.

“This is a historic day in the 26-year quest to develop an AIDS vaccine.  The results of the Thai Phase III HIV vaccine clinical trial of the “prime-boost” combination of ALVAC-HIV vaccine and AIDSVAC B/E vaccine demonstrate that a safe and effective AIDS vaccine is an achievable goal. This trial is the first demonstration in humans that, with more research, it will be possible to develop a vaccine that is fully protective against HIV.

These results represent the most significant advance in HIV vaccine research to date, and a ray of hope for the more than 2.7 million women, men and children who become newly infected with HIV every year across the globe.  Current prevention efforts can lower HIV risk, but a safe and effective vaccine will be essential to ending this epidemic.

We owe an enormous debt of thanks to the people of Thailand, and especially to the more than 16,000 women and men who selflessly participated in this clinical trial. This significant scientific milestone – the first vaccine study to reduce HIV infections in humans – would not have been reached without their engagement and the efforts of the trial sponsors – Enterprise stakeholders including the U.S. Military HIV Research Program (MHRP), the U.S. National Institute of Allergy and Infectious Diseases (NIAID), and sanofi pasteur – as well as the Thailand Ministry of Public Health and Global Solutions for Infectious Diseases (GSID).

The reduction in HIV infection risk measured in this study, 31.2 percent, was modest, but raises important implications for future research directions. HIV vaccine researchers, funders and advocates must now continue to work together, as quickly and effectively as possible, to understand why this vaccine regimen worked as it did, how its efficacy can be improved, whether and how it may work in other parts of the world, and how to develop new vaccine candidates that expand on the level of protection achieved here.

This study also demonstrates the importance of global cooperation and collaboration – the central values of the Global HIV Vaccine Enterprise – in accelerating the search for a safe and effective HIV vaccine.  Researchers, advocates, funders and policy makers are working together through the Global HIV Vaccine Enterprise process to develop and test new vaccine candidates. Full data from the Thai trial will be presented at the Enterprise’s annual scientific conference, AIDS Vaccine 2009, in Paris on October 19-22. http://www.hivvaccineenterprise.org/conference/2009/

Finally, these results are an immediate call to action to governments, funders, policy makers, researchers and advocates to dramatically step up our efforts to develop and make globally available a safe and effective HIV vaccine. Stakeholders of the Global HIV Vaccine Enterprise will continue to lead this fight, but developing a safe and effective AIDS vaccine will require the full and collective efforts of every individual and organization worldwide committed to ending this devastating epidemic.

Global HIV Vaccine Enterprise partners will be working aggressively in the months ahead to address the many scientific questions raised by this study, and to develop and test other vaccine candidates.  The findings of this trial will also help inform strategies outlined in the updated Enterprise Scientific Strategic Plan, the global strategy for HIV vaccine research currently being developed by over 150 scientists from around the world, to be released in spring 2010.

We look forward to hosting the ongoing discussion of results of this trial and the discussion of next steps in the journey to find an AIDS vaccine at the AIDS Vaccine 2009 conference in Paris, October 19-22.

Mrs. Jocelyn Rugunda, the spouse of Uganda’s representative to the United Nations, Dr Ruhakana Rugunda, has launched a The Uganda Women’s Forum. According to an invitation letter that Mrs. Rugunda sent to about 100 women in the New York area, Mrs. Rugunda states that: “The objective of the meeting is to get to know each other, share interesting life experiences, and identify opportunities of making ourselves more productive while living in United States.” Mrs. Rugunda does not indicate what qualifies her to lead Ugandan women towards making themselves more productive in America.

When we checked with a highly reliable source in the Ministry of foreign affairs, she told us that Mrs. Rugunda’s forum is “soft” recruiting for the NRM.  The source explained: “Mr. Museveni believes that Baganda women in America like him and what he is doing; it is only their husbands and boyfriends who confuse them with information about land issues and tribalism. Mr. Museveni thinks that if many of these Baganda women become NRM, the pressure from UNAA and Ggwanga Mujje will be very low. When giving clearance to Mrs. Rugunda to recruit, the permanent secretary, Ambassador James Mugume, specifically instructed Mrs. Rugunda to avoid political discussions in her forum. They are afraid that if politics is discussed in this forum, Baganda and other women may start asking why Museseveni’s is terrorizing their families in Buganda and stealing Buganda land.”

When shown Mrs. Rugunda’s invitation, a Muganda analyst and thought leader based in New York, agreed that this could be a campaign to recruit women, especially Baganda women, away from UNAA and Ggwanga Mujje activities, which the NRM does not control. He also had some tough words about Mrs. Rugunda’s character: “I have reliable information that when that woman and her husband came to New York they decided to rent an apartment in, of all places, Trump Tower. They are spending $16,000 per month on rent only and they represent a Uganda where a government medical doctor is paid $150 per month. But she now wants to help Baganda women make themselves more productive in America? I hope these women first send her an email and ask her to explain if it is not true that she has rented in Trump Towers, with rich Arab sheiks for neighbors. And how her family made the millions of dollars they have in Uganda.”

According to Mrs. Rugunda’s invitation, the Uganda Women’s’ Forum meeting will be at the Uganda House in New York on Saturday, June 27, 2009.